Maa: Yhdysvallat
Kieli: englanti
Lähde: NLM (National Library of Medicine)
FLUMETHASONE (UNII: LR3CD8SX89) (FLUMETHASONE - UNII:LR3CD8SX89)
Bimeda, Inc.
INTRAVENOUS
PRESCRIPTION
INDICATIONS Bimasone is recommended for the various rheumatic, allergic, dermatologic and other disease states which are known to be responsive to the anti-inflammatory corticoids. Equine Indications 1. Musculoskeletal conditions due to inflammation, where permanent structural changes do not exist, such as bursitis, carpitis, osselets and myositis. Following therapy an appropriate period of rest should be instituted to allow a more normal return to function of the affected part. 2. In allergic states such as hives, urticaria and insect bites. Canine Indications 1. Musculoskeletal conditions due to inflammation of muscles or joints and accessory structures, where permanent structural changes do not exist, such as arthritis, osteoarthritis, the disc syndrome and myositis. In septic arthritis appropriate antibacterial therapy should be concurrently administered. 2. In certain acute and chronic dermatoses of varying etiology to help control the pruritus, irritation and inflammation associated with these conditions. The drug has proven useful in otitis externa in conjunction with topical medication for similar reasons. 3. In allergic states such as hives, urticaria and insect bites. 4. Shock and shock-like states, (4) by intravenous administration. Feline Indications 1. In certain acute and chronic dermatoses of varying etiology to help control the pruritus, irritation and inflammation associated with these conditions. CONTRAINDICATIONS Do not use in viral infections. Except for emergency therapy, do not use in animals with tuberculosis, chronic nephritis, cushingoid syndrome and peptic ulcers. Existence of congestive heart failure, diabetes and osteoporosis are relative contraindications.
Bimasone is supplied in 100 mL vials.
Abbreviated New Animal Drug Application
BIMASONE- FLUMETHASONE INJECTION, SOLUTION BIMEDA, INC. ---------- BIMASONE (FLUMETHASONE) 0.5 MG/ML STERILE INJECTION FOR HORSES, DOGS, & CATS GLUCOCORTICOID CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian. GENERAL Flumethasone is a chemical modification of prednisolone which possesses greater anti- inflammatory and gluconeogenic properties than the parent compound when compared on an equivalent basis. Due to the potency of Bimasone, dosage recommendations should be consulted prior to drug administration. Chemically, it is 6α, 9α-difluoro-16α methylprednisolone. The structural formula is as follows: DESCRIPTION The active ingredient of Bimasone is flumethasone which occurs as a white to creamy white, odorless, crystalline powder. The appearance of Bimasone is a clear colorless to slightly yellowish mobile liquid. Each mL of the injectable preparation contains 0.5 mg flumethasone, 420 mg polyethylene glycol 400, 9 mg benzyl alcohol as a preservative, 8 mg sodium chloride, 0.1 mg citric acid, sodium hydroxide and/or hydrochloric acid for pH adjustment when necessary, and water for injection USP, q.s. CLINICAL PHARMACOLOGY Flumethasone has been reported (1) to possess 700 times the glucocorticoid activity of cortisol (hydrocortisone) as measured in the liver glycogen deposition assay in the rat; 120 times that of cortisol in the cotton pellet assay in the rat; and also in the same animal, shows a net excretion of sodium. In similar tests in rats, another report (2) showed flumethasone 730 times more potent than cortisol in the granuloma inhibition assay and 165 times the activity of cortisol in the glycogen deposition assay. The same report showed that in man, the compound possessed 7.8 times the potency of prednisolone. An additional report (3) indicated that flumethasone possessed 677 times the potency of cortisol in the liver glycogen deposition test in the rat, and 30, 25, and 31 times respectively, the eosinopenic, hyperglycemic and antirheumatic potency of corti Lue koko asiakirja